Lin BioScience, Inc.

As of June 30, 2026, Lin BioScience, Inc. carries a market capitalization of 35.20B, placing it among publicly traded companies globally. Its enterprise value stands at 33.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Lin BioScience, Inc. has 829.20M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Lin BioScience, Inc. maintains a current ratio of 38.08, meaning it holds 38.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Lin BioScience, Inc.'s stock has gained approximately 480.36% over the past 52 weeks. The 50-day moving average sits at 140.72, while the 200-day moving average is 67.19.

As of June 30, 2026, Lin BioScience, Inc. holds 16.60B in cash and equivalents against 92.72M in total debt, resulting in a net debt position of -9.63B. Total book value stands at 10.59B, with working capital of 16.41B providing operational flexibility.

Lin BioScience, Inc.'s most recent stock split took place on August 20, 2026 with a 1:10 split ratio.